Discovery of Potent EGFR Inhibitors for Del19 and L858R/T790M Mutants Through Structure‐Based Virtual Screening and Biological Evaluation
With its novel molecular scaffold and mutant‐selective inhibitory profile, XJ2‐2 represents a promising lead compound for overcoming NSCLC drug resistance and advancing the development of next‐generation EGFR inhibitors.